1. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
- Author
-
Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, Macleod PM, and Zivanovic MA
- Subjects
- Bone Neoplasms pathology, Bone Neoplasms radiotherapy, Humans, Male, Platelet Count radiation effects, Radiotherapy Dosage, Strontium Radioisotopes therapeutic use, Bone Neoplasms secondary, Palliative Care methods, Prostatic Neoplasms pathology, Strontium therapeutic use
- Abstract
In a multi-centre study strontium-89 was shown to be effective in relieving bone pain from prostatic carcinoma in patients who had failed conventional therapies. Of 83 patients assessed at 3 months, following the administration of a dose of at least 1.5 MBq/kg, 75% derived benefit and 22% became pain free. Symptomatic improvement usually occurred within 6 weeks and continued for between 4 and 15 months (mean 6 months). Based on the dose estimation part of this study the recommended dose of strontium-89 is 150 MBq. Toxicity was low, provided platelet levels were above 100 x 10(9) l-1 at the time of treatment. Repeat treatments with strontium-89 may be given at intervals of not less than 3 months. Strontium-89 is administered intravenously on an out-patient basis with no special radiological protection precautions.
- Published
- 1991
- Full Text
- View/download PDF